Immunology

We are driven by science and intent on purposeful discovery, with the goal of delivering transformative medicines that make a difference for people living with chronic debilitating diseases.


Dedicated to our goal of delivering new solutions

Our constant curiosity and specialist approach drive our innovation and bring new ideas to life. We have a proud history of advancing care in multiple sclerosis and pioneering new discoveries in immunology & immune-based diseases for more than 20 years.

We are growing a strategic pipeline with a range of new potential therapies that may be able to alter treatment paradigms for chronic conditions, such as multiple sclerosis (MS), systemic lupus erythematosus (SLE) and forms of arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA).

We are discovering new ways to optimize outcomes for a range of chronic progressive diseases by pursuing novel pathways that can modulate the immune system in a more targeted way than traditional immunosuppressants.

For immune disorders, we develop approaches that target the innate and adaptive components of the immune system. This includes inhibiting the inappropriate immune activation that contributes to the disorder, as well as enhancing immune tolerance, which trains the body not to react to autoreactive triggers.

For the treatment of certain types of arthritis, our investigational therapies are being developed to potentially feature approaches that may facilitate cartilage repair homeostasis (a balance of re-growing cartilage and stopping cartilage from breaking down).

We aim to deliver first & best in class therapies to patients, we continue to combine our world-class internal scientific expertise with strategic external partnerships and collaborative research alliances that maximize the opportunities for our pipeline and optimize our R&D.

Browse the programs in our pipeline to see our current focus.  Learn more

Examples of our Network of Immunology Alliances

Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research

Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research

Since 2004, Merck KGaA, Darmstadt, Germany, and INSPE have been working together to develop pre-clinical and clinical research projects in the field of neurodegenerative diseases. The research is focusing on developing innovative therapies against serious and disabling neurological diseases, particularly those that affect young adults, such as multiple sclerosis.

Avillion

Avillion

In a collaboration model that is recently emerging in the biopharma industry, Avillion, which is amongst the pioneers of such models, will be responsible for developing anti IL-17 A/F Nanobody® from Phase II through Phase III.

Nordic Bioscience

Nordic Bioscience

Under the terms of the agreement, Nordic Bioscience will provide clinical development services in a shared risk model for our investigational drug sprifermin (recombinant human FGF-18) in osteoarthritis of the knee. We retain full responsibility for the development and commercialization of the investigational drug.  

Massachusetts General Hospital

Massachusetts General Hospital

EMD Serono is working jointly with MGH investigators to better characterize and validate the expression of investigative therapeutic targets, pathogenic immune cell types and biomarkers in SLE and LN patients.

Lupus Research Alliance

Lupus Research Alliance

As members of the Lupus Industry Council EMD Serono helps industry and academia work collaboratively, along with the Lupus Research Alliance, to address common impediments and accelerate shared research goals related to the development of new and potentially effective therapies for lupus patients.

International Progressive Multiple Sclerosis alliance

International Progressive Multiple Sclerosis alliance

As a member of the PMSA industry forum, EMD Serono works together with other industry leaders under the governance structure of global MS advocacy organizations to foster collaboration while also ensuring a patient-centered approach to drug discovery and development. Together the alliance aims to accelerate research towards the overarching goal of developing safe and effective treatments for progressive MS.

Addressing Lupus Pillars for Health Advancement (ALPHA) Project

Addressing Lupus Pillars for Health Advancement (ALPHA) Project

The ALPHA Project was launched in partnership with founding partner EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany) and through additional support by GlaxoSmithKline. The Project is a comprehensive, multi-phase, global consensus initiative aimed not only at identifying and prioritizing the top challenges in the lupus field, but also creating actionable solutions to address these issues and stimulate progress.

US/NPR/0517/0230(1)h(2)c  

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement